Warning  Please take our Crypto Currency survey here
London South East Logo | UK Share Price information



Register
Login:
Share:
Email Facebook Twitter




Scancell Holdings Share Chat (SCLP)



Share Price: 10.85Bid: 10.70Ask: 11.00Change: 0.00 (0.00%)No Movement on Scancell Hldgs
Spread: 0.30Spread as %: 2.80%Open: 10.85High: 10.85Low: 10.75Yesterday’s Close: 10.85


Share Discussion for Scancell Holdings


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


dragon101
Posts: 756
Off Topic
Opinion:No Opinion
Price:10.85
Boom!
Today 18:03
Juno up 48% on potential Celgene deal!!
 
Wildforce
Posts: 9,286
Observation
Opinion:Strong Buy
Price:10.85
Crumbs
Today 17:26
For a charity, Cancer research UK certainly seems to be looking to the future with business like eyes !

Take care ..
crumbs
Posts: 11,589
Off Topic
Opinion:No Opinion
Price:10.85
I'd be surprised
Today 17:05
If CRUK are not very interested in taking modi 1 into trial... who else might be though...
crumbs
Posts: 11,589
Off Topic
Opinion:No Opinion
Price:10.75
RE: Interesting RG retweet
Today 16:54
CRUK version might be less adverse to cut n paste

http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2018-01-17-cancer-research-uk-and-the-institute-of-cancer-research-london-join-forces-with-merck-in-new-drug

Cancer Research UK£s Commercial Partnerships Team and The Institute of Cancer Research, London (link is external), announced a multi-project collaboration and licensing deal with Merck (link is external), a leading science and technology company, to discover and develop new anticancer drugs.

"It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and clinical discoveries.£ - Dr Iain Foulkes
This multi-project deal follows previous single project drug discovery collaborations and a more recent target validation collaboration between Merck and Cancer Research UK£s Cancer Therapeutics Unit (link is external) at The Institute of Cancer Research (ICR).

The parties will collaborate on three independent research projects spanning target hit discovery to preclinical candidate nomination. This work will progress the discovery and development of potential cancer drugs, as well as develop biomarkers for target engagement and patient selection.
crumbs
Posts: 11,589
Off Topic
Opinion:No Opinion
Price:10.75
Interesting RG retweet
Today 16:50
You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.

The company is teaming up with Cancer Research UK and the Institute of Cancer Research, London for three research projects and a licensing deal. The group will be doing discovery-stage work looking for targets and preclinical candidates.

Under the deal, Merck has worldwide rights to take molecules discovered through the collaboration through clinical development. Cancer Research UK and the ICR could get milestone payments if they reach certain R&D, regulatory and sales goals. They£re also eligible to receive royalty payments on net sales of future products.
https://endpts.com/merck-kgaa-taps-uk-cancer-research-organizations-to-feed-pipeline/
CHELSEA7
Posts: 29,739
Premium Chat Member
Off Topic
Opinion:Hold
Price:10.75
NEX so far
Today 14:13
17/01/2018 13:19 30,000 10.54
17/01/2018 10:40 10,000 10.72
Ddug
Posts: 4,957
Off Topic
Opinion:No Opinion
Price:10.85
RE: Ddug
Today 13:30
After I bought yesterday it closed up 50% so a little re Trace is to be expected, been a long time since I bought in at the bottom of a bull run. I am sure when it's scancell's turn holder's won't be disappointed.
CHELSEA7
Posts: 29,739
Premium Chat Member
Off Topic
Opinion:Hold
Price:10.85
RE: Ddug
Today 13:15
Good luck there, noticed that is down 14% today, the curse of the d dug?? Who knows anymore, movements over the last few months of a few make me feel it is better to be out of AIM!!

One thing from the BioNTech agreement is they would have done due diligence on us, that will do for me right now. ATB
Ddug
Posts: 4,957
Off Topic
Opinion:No Opinion
Price:10.85
RE: Ddug
Today 13:00
I nearly bought in here yesterday, decided N4P was a better choice short term. Nice rise there yesterday so pleased I called that right, but, I am always aware that being out of scancell could be a costly mistake when news finally lands.
CHELSEA7
Posts: 29,739
Premium Chat Member
Off Topic
Opinion:Hold
Price:10.85
RE: Ddug
Today 12:47
Needless to say, doesn"t mean those who have bought quite a few in recent days have called it wrong either, whatever rocks your boat!!




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.